ClinicalTrials.gg
CompletedNCT07758452DIR-IDDUpdated Aug 13, 2026

Effectiveness of DIR/Floortime™ in Children With Intellectual Developmental Disorder

An interventional study of DIR/Floortime™ and Standard therapy in Intellectual Developmental Disorder, sponsored by GIFT University. Completed at 1 site in Pakistan. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by GIFT University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2026, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effectiveness of Integrated Developmental, Individual-differences, Relationship-based (DIR)/Floortime™ intervention in improving functional emotional development and adaptive behavior in children with Intellectual Developmental Disorder (IDD). Participants aged 4-12 years will be randomly assigned to receive either DIR/Floortime™ in addition to standard therapy or standard therapy alone for 10 weeks. Outcomes will be assessed using the Functional Emotional Assessment Scale (FEAS) and the Vineland Adaptive Behavior Scales (VABS).

Read the detailed description

Intellectual Developmental Disorder (IDD) is characterized by significant limitations in intellectual functioning and adaptive behavior, affecting conceptual, social, and practical skills. Although conventional therapeutic interventions support developmental progress, many children continue to experience challenges in communication, social interaction, daily living skills, and functional emotional development. The Developmental, Individual-differences, Relationship-based (DIR)/Floortime™ model is a relationship-based intervention designed to enhance emotional, social, and developmental capacities through child-led interactions.

This study is a parallel-group randomized controlled trial evaluating the effectiveness of Integrated DIR/Floortime™ in children with IDD. Participants aged 4-12 years will be randomly assigned to either an experimental group receiving DIR/Floortime™ in addition to standard therapy or a control group receiving standard therapy alone. The intervention will be delivered over a period of 10 weeks.

The primary outcomes include communication, socialization, daily living skills, and functional emotional development. These outcomes will be measured using the Vineland Adaptive Behavior Scales (VABS) and the Functional Emotional Assessment Scale (FEAS) at baseline and after completion of the 10-week intervention. The findings will contribute to the evidence regarding the effectiveness of DIR/Floortime™ for children with Intellectual Developmental Disorder.

02

Conditions studied

  • Intellectual Developmental Disorder

Keywords

  • Intellectual developmental disorder
  • FEAS
  • VABS
  • IDD
  • DIR/Floortime
03

In context

Intellectual Disability

388 studies on the registry are indexed under Intellectual Disability; 106 are open to participants now.

This study's enrollment of 24 is below the median of 59 across 249 interventional studies indexed under Intellectual Disability.

Browse Intellectual Disability studies →

Lead sponsor

GIFT University is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4-12 years.
  • Clinical diagnosis of Intellectual Developmental Disorder (IDD) according to criteria.
  • Mild to moderate intellectual developmental impairment.
  • Receiving routine therapeutic services.
  • Able to participate in the 10-week DIR/Floortime™ intervention and study assessments.
  • Written obtained from a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Profound or severe Intellectual Developmental Disorder preventing meaningful participation in the intervention.
  • Severe visual, hearing, or physical impairments that would interfere with assessments or intervention.
  • Major neurological or genetic disorders that could affect study participation.
  • Serious medical or psychiatric conditions requiring intensive treatment.
  • Participation in another intervention study during the study period.
  • Parent or legal guardian unwilling to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    DIR/Floortime + Standard Therapy

    Participants receive Integrated DIR/Floortime™ in addition to their routine standard therapeutic services for 10 weeks.

    Behavioral: DIR/Floortime™

  • Active comparator
    Standard Therapy

    Participants continue to receive routine standard therapeutic services without the addition of DIR/Floortime™ for 10 weeks.

    Behavioral: Standard therapy

Interventions

  • BehavioralDIR/Floortime™

    Integrated Developmental, Individual-differences, Relationship-based (DIR)/Floortime™ intervention delivered for 10 weeks in addition to standard therapy

  • BehavioralStandard therapy

    Routine therapeutic services provided without DIR/Floortime™ during the 10-week study period.

06

What researchers measure

Primary outcomes

  1. Communication Skills

    Change in Communication Skills measured using the Vineland Adaptive Behavior Scales, Third Edition (VABS-3), Communication domain Growth Scale Values (GSVs). GSVs range from 10 to 197, with higher scores indicating better adaptive functioning.

    Time frame: Baseline and Week 10

  2. Socialization Skills

    Change in Socialization Skills measured using the Vineland Adaptive Behavior Scales, Third Edition (VABS-3), Socialization domain Growth Scale Values (GSVs). GSVs range from 10 to 197, with higher scores indicating better adaptive functioning.

    Time frame: Baseline and Week 10

  3. Daily Living Skills

    Change in Daily Living Skills measured using the Vineland Adaptive Behavior Scales, Third Edition (VABS-3), Daily Living Skills domain Growth Scale Values (GSVs). GSVs range from 10 to 197, with higher scores indicating better adaptive functioning.

    Time frame: Baseline and Week 10

  4. Functional Emotional Development

    Change in functional emotional development measured using the Functional Emotional Assessment Scale (FEAS). FEAS items are scored from 0 to 2, with higher scores indicating better functional emotional development. Symbolic, Sensory, and Examiner scores are assessed.

    Time frame: Baseline and Week 10

07

Study locations

1 site
  • SEND Therapy Center
    Gujranwala, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data (IPD) will not be shared. The study involves confidential data from children with Intellectual Developmental Disorder, and participant privacy and confidentiality will be protected in accordance with institutional ethical approval and informed consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 3 months.

Of 155 non-industry interventional studies with no phase under Intellectual Disability, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 3 months is below that.

Counting every sponsor, half of 158 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2026
First posted
Aug 11, 2026
StartActual
Mar 16, 2026
Primary completionActual
Jul 15, 2026
CompletionActual
Aug 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07758452
Lead sponsor
GIFT University
Responsible party
Fatima Tabassum (Principle investigator, GIFT University) — Principal investigator
First posted
Aug 11, 2026
Start date
Mar 16, 2026
Primary completion
Jul 15, 2026
Completion
Aug 1, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion